Abstract: With the change of diet structure and lifestyle, the number of type 2 diabetic patients with non-alcoholic fatty liver has been increasing. The relevant molecules in the pathogenesis include FGF21, Fetuin-A, SREBP-1, PPARα, IGFBP-1, IGF-1, TNF-α, CTRP3, and AMPK. It is expected that in the near future, highly effective drugs for the treatment of non-alcoholic fatty liver can be developed for its molecular targets.

Key words: type 2 diabetes, non-alcoholic fatty liver, molecular mechanism